In summary, this analysis demonstrated that pharmacological VPS34 inhibition in renal cancer leads to an anti‐tumor immune response characterized by proinflammatory cytokine/chemokine release and increased expression of IFN response genes. This evidence concerns the gene IFNA1 and renal carcinoma.